![]() It's unclear what role they'll play in cancer care. Research into NK cell treatments remains early, and the field has significant hurdles still to overcome, like proving how potent their effects are and how long they last. ![]() ![]() Some efforts are even underway to combine NK cell therapies with other medicines, among them CAR-T treatments. Their developers aim to prove they're safer than their CAR-T counterparts, more convenient and potentially able to broaden the cell therapy's reach to more cancers. Unlike the CAR-T cell therapies approved for a handful of blood cancers, natural killer cell therapies rely on NK cells, the body's front-line defenders, to seek out and attack tumors. Wall Street analysts, for example, noted the responses Fate observed weren't "deep" and most occurred in patients who may have been easier to treat. The results are the latest piece of evidence suggesting NK cell therapies could eventually become an effective, off-the-shelf treatment for blood cancer - a strategy being pursued by Fate, Nkarta Therapeutics, Takeda and others.There were no instances of the neurological or immune-related side effects seen with other forms of cell therapy and there were also no side effects that would prevent testing of higher doses, according to the company. Four of nine patients who received one Fate NK cell therapy showed evidence of a response, as did one of three who got a different type of NK cell therapy.Fate Therapeutics on Thursday reported new results from two early-stage studies testing two types of experimental leukemia treatments that use natural killer cells, an emerging form of cancer immunotherapy.
0 Comments
Leave a Reply. |